RE-PHIRE (Recruiting)

A Phase 2b Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Patients with Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WHO Group 2)